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1 |  INTRODUCTION
Epilepsy is a neurological disease characterized by the 
presence of spontaneous and recurrent seizures.1 About 
50 million people worldwide suffer epilepsy.2 Despite the de-
velopment of new antiepileptic medications over the last dec-
ades, 30% of patients with epilepsy continue having seizures, 
resulting in the named drug-resistant epilepsy. Drug-resistant 
epilepsy is associated with comorbid psychiatric and psycho-
logical disorders, severe economic and social impairments, 
and high risk of suicide as well as sudden unexpected death 
(SUDEP).3,4 The high prevalence of drug-resistant epilepsy 
has generated the search of new solutions using old drugs.
2 |  IS CANNABIS AN OPTION FOR 
EPILEPSY?
Cannabis, one of the oldest plants that humans grow, was 
used in the Middle East to control nightly seizures around 
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Abstract
Cannabis has been considered as a therapeutic strategy to control intractable epilepsy. 
Several cannabis components, especially cannabidiol (CBD), induce antiseizure ef-
fects. However, additional information is necessary to identify the types of epilepsies 
that can be controlled by these components and the mechanisms involved in these 
effects. This review presents a summary of the discussion carried out during the 
2nd Latin American Workshop on Neurobiology of Epilepsy entitled “Cannabinoid 
and epilepsy: myths and realities.” This event was carried out during the 10th Latin 
American Epilepsy Congress in San José de Costa Rica (September 28, 2018). The 
review focuses to discuss the use of CBD as a new therapeutic strategy to control 
drug-resistant epilepsy. It also indicates the necessity to consider the evaluation of 
unconventional targets such as P-glycoprotein, to explain the effects of CBD in drug-
resistant epilepsy.
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1800 BC.5 Experimental evidence obtained during the 1970s-
1980s indicates that “phytocannabinoids” obtained from can-
nabis exerted anticonvulsant effects in experimental models 
of both, acute seizures6‒9 and epilepsy.10‒14
During the last decade, the use of cannabis extracts has 
been of great interest in the control of drug-resistant epi-
lepsy, mainly in children with severe (catastrophic) epileptic 
syndromes, that is, neurological syndromes associated with 
seizures difficult to control and cognitive dysfunction such 
as Dravet (pathogenic variants in the sodium channel gene 
SCN1A) or Lennox-Gastaut syndromes. Clinical evidence 
supports that pediatric and adult patients with refractory 
epileptic disorders may achieve a significant improvement 
with the administration of cannabis (Table 1). However, 
other studies indicate that the effectiveness of phytocanna-
binoids as antiseizure therapy is contradictory.15,16 Based on 
the information described above, the National Academy of 
Science, Engineering and Medicine of the USA indicates that 
at present, the evidence to support the use of cannabinoids in 
epilepsy is insufficient.17
The conflicting results about cannabis failure or success 
in epilepsy can be explained by several circumstances. First 
of all, the pharmacokinetics and pharmacodynamics of can-
nabinoids depend on the formulation and route of administra-
tion. Indeed, some effects of cannabinoids are explained by 
pharmacokinetic interactions such as inhibition or induction 
of enzymes involved in drug metabolism.18 Other important 
issue is that the bioavailability of cannabinoids applied by 
oral administration in liquid formulations augments with the 
fed state, especially with high-fat meals.19
On the other hand, the effects of cannabis on specific 
types of epilepsy are unknown. Concerning this issue, few 
studies exist about the effects of cannabis extracts in tempo-
ral lobe epilepsy, the most common drug-resistant epileptic 
syndrome in adults (see below). The influence of clinical 
factors (age of patient, gender, etc) in the efficacy of canna-
bis has not been considered in clinical studies. Other factor 
that can modify the effects of cannabis is its coadministration 
with other drugs, especially antiseizure drugs. Few data exist 
about the pharmacokinetic and pharmacodynamic interaction 
between cannabis and other drugs.20 However, no informa-
tion exists about the pharmacokinetic and pharmacodynamic 
interaction between cannabis and antiseizure drugs.
An important condition that explains the contradictory ef-
fects of cannabis on epilepsy is that this plant contains more 
than 480 compounds, including noncannabinoids such as 
prenylated flavonoids, stilbenoids derivatives, and lignanam-
mides.21 The content of the different chemical components in 
cannabis depends on each species. Cannabis ruderalis con-
tains the lowest concentrations of Δ9-tetrahydrocannabidiol 
(THC).22 European Cannabis sativa contains more cannabi-
diol (CBD) than THC, whereas Asian Cannabis indica has 
more THC than CBD.23
Although artisanal cannabis is considered a “miracle ther-
apy,” at present there are not regulations to maintain the qual-
ity and purity of the drug during the obtaining procedure. 
Artisanal cannabis oil may contain abiotic (dust, fertilizers) 
and biotic (ie, insect, fungi, bacteria) contaminants, heavy 
metals, pesticides, etc,24 a situation that represents a high risk 
to the health of patients. Unfortunately, the evaluation of the 
effects of artisanal cannabis is difficult, has yielded contro-
versial results, and lacks controlled clinical studies.25
There is an apparent disregard for long-term use of canna-
bis. Long-term cannabis administration augments the risk of 
addiction and is associated with side effects such as chronic 
bronchitis. It also enhances the possibility to present psy-
chosis and schizophrenia in persons with a predisposition to 
such disorders. Adolescents are more vulnerable to the side 
effects of chronic cannabis use as there is altered brain de-
velopment, cognitive impairment, poor academic outcomes, 
etc26. According to this information, it is evident the neces-
sity to obtain more information concerning the beneficial ef-
fects of cannabis oil in the control of drug-resistant epilepsy 
and stablish standardized procedures to obtain homogeneous 
products. In addition, it is essential to elucidate the contribu-
tion of each compound in the therapeutic effects induced by 
cannabis.
3 |  IS CANNABIDIOL A NEW 
HOPE FOR DRUG-RESISTANT 
EPILEPSY?
At present, there are studies indicating that some can-
nabis products may induce antiepileptic effects. These 
products are THC, CBD, Δ9-tetrahydrocannabivarin, can-
nabidivarin, and Δ9-tetrahydrocannabinolic acid.27,28 The 
main phytocannabinoids evaluated with this purpose are 
THC and CBD. THC is an active ingredient of cannabis 
plant that induces psychoactive effects, augments oxida-
tive stress, and produces mitochondrial dysfunction in the 
brain, conditions that increase the risk to stroke and brain 
damage.29,30 For these reasons, low interest exists about 
THC as an antiseizure drug.
Key points
• Conflicting results exist about the use of artisanal 
cannabis to control drug-resistant epilepsy
• Cannabidiol is a multitarget drug that represents a 
new hope to control drug-resistant epilepsy
• Cannabidiol may act on unconventional central 
and peripheral targets to control drug-resistant 
epilepsy

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cannabidiol is the most abundant phytocannabinoid in 
cannabis. It has a terpenophenolic structure and hydroxyl 
groups in carbons 1 and 3.31 CBD shares lipophilic charac-
teristics with the rest of the cannabinoids, lacks psychoactive 
effects,32 and induces neuroprotective effects.33
The metabolism of CBD comprises oxidation and hy-
droxylation through different enzymes of the cytochrome 
P450 family (CYP450) (Figure 1).34‒36 In vitro studies using 
human liver microsomes revealed that 6α-hydroxylation 
of CBD is mediated by CYP3A4 and CYP2C19 isoforms, 
6β-hydroxylation is induced by CYP3A4, whereas 7-hydrox-
ylation is mediated by CYP2C19.35 Glucuronosyltransferase 
and sulfotransferases enzymes are also involved in the me-
tabolism of CBD.36,37 At present, more than fifty metab-
olites from CBD have been identified in urine.34,38 The 
most abundant metabolites are 7-carboxy-cannabidiol 
(7-COOH-CBD), 7-hydroxy-cannabidiol (7-OH-CBD), and 
6-hydroxy-cannabidiol (6-OH-CBD). Although the biolog-
ical activity of many of CBD metabolites is unknown,36,39 
preclinical studies suggest that 7-OH-CBD obtained from 
humans induces anticonvulsant effects in mice.40
On the other hand, CBD is a potent inhibitor of CYP1A1, 
CYP2B6, CYP2D6, and CYP2C19 with a subsequent reduc-
tion in the metabolism of some drugs. This condition explains 
the increases in the serum levels of THC, topiramate, rufin-
amide, clobazam, and N-desmethylclobazam when they are 
coadministered with CBD.41‒43 This effect is more evident 
when the drugs are oral administered.44 These studies lead to 
suggest that CBD augments the effects of antiseizure drugs. 
This idea is supported by the early observational clinical study 
carried out by Cunha et al,45 who described for the first time 
that the chronic administration of CBD reduced the seizure 
activity in seven of eight patients with drug-resistant temporal 
lobe epilepsy. During the CBD treatment, the patients received 
the administration of the antiseizure drugs prescribed before 
the study. According to this information, it is evident the ne-
cessity of clinical studies focused to determine the effects of 
CBD in different experimental models of drug-resistant epi-
lepsy and its pharmacokinetic interactions with other drugs.
Several studies support that CBD could be effective in 
the control of epilepsy.46 Results obtained from experimental 
models reveal that CBD reduces the seizure activity47‒49 and 
delays the epileptogenesis process, effects associated with 
neuroprotection.50,51 CBD in oral solution (Epidiolex®) is 
considered a therapy to control seizures associated with the 
Lennox-Gastaut syndrome,52 Dravet syndrome,53 and infan-
tile spasms.54 Indeed, the US Food and Drug Administration 
(FDA) recently approved Epidiolex for the control of seizures 
associated with Lennox-Gastaut syndrome and Dravet syn-
drome, in children (2 years of age and older) and adults.55
The antiepileptic, anxiolytic, antipsychotic, and neuro-
protective effects induced by CBD lead to suggest that it is 
an excellent candidate to control drug-resistant epilepsy and 
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comorbid disorders.56 This notion is supported by results ob-
tained from experimental models of temporal lobe epilepsy, 
a neurological disorder with a high prevalence of drug resis-
tance and comorbid psychiatric symptoms.57 CBD induces 
neuroprotection, decreased neuronal excitability, and avoids 
cell death in the hippocampus of animals with temporal lobe 
epilepsy.50,58 However, the effects of CBD in other types of 
drug-resistant epilepsy are not conclusive due to the presence 
of subjects who do not respond to the treatment.59‒62
Clinical data in humans indicate that CBD-rich extracts 
are more effective to reduce the seizure frequency when com-
pared with purified CBD. In addition, CBD-rich extracts re-
duce the seizure activity with a significantly lower average 
daily dose, supporting a higher potency when compared with 
purified CBD. These effects are associated with side effects 
such as appetite alterations, nausea, diarrhea and other gas-
trointestinal alterations, sleepiness, weight changes, and fa-
tigue, among others.63 It is known that THC augments the 
analgesic effects of CBD.64 On the other hand, CBD potenti-
ates or reduces some effects induced by THC.65 However, it 
is unknown whether the THC and CBD interaction facilitates 
or reduces the seizure activity.
4 |  CONVENTIONAL 
EFFECTS THAT EXPLAIN THE 
ANTIEPILEPTIC EFFECTS OF 
CANNABIDIOL
Different targets are involved in the mechanisms by 
which CBD induces antiepileptic effects. Computational 
analysis and ligand displacement assays revealed that 
CBD augments the levels of endocannabinoids (ananda-
mide) as result of the inhibition of the fatty acid-binding 
proteins (FABPs) that mediate the anandamide trans-
port to its catabolite enzyme (fatty acid amide hydrolase 
[FAAH]).43 On the other hand, experiments indicate that 
CBD is a very low-affinity ligand at CB1 and CB2 re-
ceptors inducing antagonism.66 It acts as agonist on D2 
(partial agonist)67 and 5-HT1A receptors.
68,69 CBD is an 
agonist of TRPV1 channels27 and activator of TRPV2 
channels.70 It is an allosteric modulator of mu- and delta-
opioid receptors.71 CBD induces resting-state blockage 
of sodium channels and blocks the voltage-gated po-
tassium channel  subunit Kv2.1.72 Studies indicate that 
CBD produces neuroprotection by activation of CB2 and 
F I G U R E  1  Schematic diagram indicating the different enzymes of the cytochrome P450 family (CYP450) involved in the metabolism of 
cannabidiol (CBD)
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adenosine A2 receptors.73 In experimental models of pain, 
CBD induces analgesic effects through the activation of 
5HT1A and TRPV1 channels.
74,75 Using blood-brain bar-
rier (BBB) modeled with human brain microvascular en-
dothelial cell and astrocyte co-cultures, it was found that 
CBD induces neuroprotection in ischemic stroke by acti-
vation of PPARγ and 5-HT1A receptors.
76 CBD injected 
into the dorsolateral periaqueductal gray of rats exerts 
anxiolytic-like effects through the activation of 5-HT1A 
receptors (Figure 2).77
CBD has been suggested to play a critical role in the 
glutamatergic neurotransmission. However, the findings 
are controversial. CBD induces antidepressant-like effects 
associated with enhanced serotonin and glutamate neuro-
transmission in a mouse model of depression.78 Other stud-
ies indicate that CBD reduces the overactivity of NMDA 
receptors through the antagonism of the sigma 1 receptors 
(σ1R).79 CBD also reduces glutamate release and protects 
from convulsive activity in an experimental model of sei-
zures induced by cocaine.80 The effect of CBD on the glu-
tamatergic neurotransmission is relevant because excess of 
extracellular levels of glutamate is associated with recur-
rent seizures and chronic epilepsy.81 Indeed, the blockage 
of NMDA receptors can prevent and in some cases reverse 
certain pathological conditions associated with neurologi-
cal disorders, including epilepsy.82,83
High glutamatergic neurotransmission, neuroinflamma-
tion, and oxidative stress are interconnected phenomena that 
occur in the brain of subjects with epilepsy. Interestingly, the 
increase in the oxidative stress and neuroinflammation asso-
ciated with drug-resistant epilepsy can be reverted when the 
seizure activity decreases as result of the surgical resection of 
the epileptic foci.84‒86
Seizure-induced neuroinflammation is a condition as-
sociated with the increase of cytokines such as interleukin 
(IL)-1β, tumor necrosis factor (TNF), transforming growth 
factor (TGF)-β, and danger signals such as High Mobility 
Group Box 1 (HMGB1). The activation of cytokines may 
underlie hyperexcitability and neurotoxicity, a situation 
that facilitates the epileptic activity.87‒89 Concerning this 
issue, it is described that IL-1β induced in activated astro-
cytes and microglia contributes to the occurrence of seizure 
activity.90,91 IL-1β and TNF produce excitatory effects by 
enhancement of Ca2+ influx and extracellular levels of glu-
tamate with a subsequent production of hydroxyl radicals. 
TNF also modifies the glutamate subunit receptor compo-
sition of neurons and augments the glutamate release from 
microglia. In astrocytes, TNF enhances Ca2+ mobilization 
with a subsequent cyclooxygenase enzyme-2 (COX-2) acti-
vation, prostaglandin-2 synthesis, and glutamate release.92,93
Oxidative stress is a condition detected during epi-
leptogenesis and chronic epilepsy. It is a consequence of 
mitochondrial dysfunction and increased activity of nico-
tinamide adenine dinucleotide phosphate oxidase (NOX), 
xanthine oxidase, and inducible nitric oxide synthase 
(iNOS) that result in the production of reactive oxygen spe-
cies (ROS) and reactive nitrogen species (RNS). Oxidant 
stress facilitates inflammation through the induction of 
COX-2 gene expression and ictogenic cytokines.93,94 The 
high glutamate release and NMDA receptor activation in 
chronic epilepsy can also facilitate oxidative mechanisms 
and neurotoxicity.95,96
F I G U R E  2  Mechanisms of action of 
cannabidiol (CBD) on different receptors, 
channels, and P-glycoprotein transporter
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Experimental evidence supports that CBD represents a 
novel strategy to reduce oxidative stress, excitotoxicity, and 
neuroinflammation in neurodegenerative disorders.  CBD 
decreases  oxidative stress, mitochondrial dysfunction and 
reactive oxygen species generation, effects associated with 
reduced neuroinflammation.97 CBD also augments microg-
lial phagocytosis by the modification of TRPV channel ac-
tivity.98 It induces anti-inflammatory effects by decreasing 
the plasma levels of prostaglandin E2, the production of 
free radicals, and the activity of COX-1/COX-2.99,100 CBD 
reduces neuronal damage, astrogliosis, excitotoxicity, and 
neuroinflammation in experimental models of ischemia.101 
However, the immune effect of CBD can vary depending on 
the concentrations administered as well as the type and/or 
magnitude of stimulus.102
5 |  CANNABIDIOL MAY ACT 
ON UNCONVENTIONAL CENTRAL 
AND PERIPHERAL TARGETS TO 
CONTROL DRUG-RESISTANT 
EPILEPSY
P-glycoprotein is a BBB efflux transporter that limits drug 
accumulation in the brain. Its overexpression at the luminal 
side of the BBB is associated with drug-resistant epilepsy 
because it results in a low penetration of antiseizure drugs 
into the brain.103,104 P-glycoprotein is also overexpressed in 
astrocytes and neurons in brain tissue obtained from patients 
and animals with drug-resistant epilepsy.105,106
The enhanced extracellular levels of glutamate pro-
duced in the brain of subjects with drug-resistant epilepsy107 
represent a mechanism that facilitates the overexpres-
sion of P-glycoprotein in a COX-2-dependent manner.108 
P-glycoprotein overexpression in cells of the BBB can also re-
sult from chronic oxidative stress or prolonged neuroinflam-
mation.109,110 According to several experimental evidence, 
the administration of inhibitors of P-glycoprotein function 
or expression represents a potential therapeutic strategy to 
control drug-resistant epilepsy.81,111 Concerning this issue, 
the use of celecoxib, a specific COX-2 inhibitor, reverts the 
P-glycoprotein overexpression and facilitates brain delivery 
of antiseizure drugs in animals with epilepsy.112 The adminis-
tration of P-glycoprotein inhibitors such as verapamil induces 
encouraging effects in patients with drug-resistant epilepsy. 
However, these drugs may induce significant side effects that 
restrict their clinical application.113 Experimental evidence 
also supports that a better control of drug-resistant epilepsy 
could be obtained if antiseizure drugs are associated with 
P-glycoprotein inhibitors.111,114,115
Studies indicate that CBD down-regulates the protein 
and mRNA expression of P-glycoprotein and inhibits its ef-
flux function in trophoblast cell lines.116 CBD also interacts 
with a specific site of the P-glycoprotein interfering with the 
ATPase activity stimulated by substrates and consequently 
decreasing the energy required for their transport in Caco-2 
and LLC-PK1/MDR1 cells.117 The inhibitory effect of CBD 
on P-glycoprotein is evident after prolonged, but not short-
term exposure, in cells CEM/VLB100 that overexpress this 
transporter.118
It is important to mention that CBD is not a substrate of 
P-glycoprotein. In mice, experiments revealed that the over-
expression of this transporter at BBB does not limit the brain 
uptake of CBD.119 This condition associated with the inhib-
itory effect of P-glycoprotein at BBB plus its anticonvulsant 
and neuroprotective effects suggests that CBD can be an at-
tractive adjunctive therapy to control drug-resistant epilepsy. 
However, further studies are necessary to demonstrate that the 
exposure to CBD blocks the activity of P-glycoprotein and/or 
reverts its overexpression in neurons and astrocytes in brain 
tissue obtained from subjects with drug-resistant epilepsy.
The overexpression of P-glycoprotein in neurons is as-
sociated with high membrane depolarization, a condition 
that may facilitate the epileptiform activity.120 Interestingly, 
P-glycoprotein overexpression is also induced in cardiomy-
ocytes of subjects submitted to repetitive convulsive sei-
zures. This condition is related with electrocardiographic 
(ECG) alterations and SUDEP as consequence of a depolar-
izing role in cardiomyocytes.121 If CBD is able to revert the 
P-glycoprotein overexpression and its depolarizing condition 
in heart, it may represent a novel strategy to reduce SUDEP 
in drug-resistant epilepsy. However, further experiments are 
necessary to support this hypothesis.
In addition to the pharmacological mechanisms pre-
viously described, CBD also induces epigenetic changes 
associated with neuroprotective effects. Concerning this 
issue, it is known that iron accumulation in brain regions 
is a condition that contributes to neurodegeneration. CBD 
restores the basal levels of hippocampal dynamin-1-like 
protein (DNM1L), caspase 3, and synaptophysin in animals 
with cell damage subsequent to iron loading.122 These ef-
fects are also associated with reversion of the iron-induced 
mitochondrial deoxyribonucleic acid (mtDNA) deletions, 
the decreased epigenetic modulation of mtDNA, as well 
as restauration of the mitochondrial ferritin levels and 
succinate dehydrogenase activity.123 According to these 
studies, CBD induces epigenetic effects that results in the 
restauration of the normal cellular function and neuropro-
tection. Epigenetic effects induced by CBD hold promise 
as a future therapeutic strategy for drug-resistant epilepsy. 
However, further research is essential to determine side ef-
fects induced by CBD when applied chronically, alone or 
combined with other antiseizure drugs inducing epigenetic 
effects such as valproic acid.124
On the other hand, the repeated coadministration of CBD 
with THC induces histone 3 acetylation (H3K9/14ac) in 
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the ventral tegmental area, an epigenetic effect related with 
addiction processes.125 These effects should be considered 
when apply CBD chronically because H3K9 acetylation is 
significantly augmented as result of seizure activity, a condi-
tion associated with the activation of TLR4 and subsequent 
inflammation process.126
6 |  CONCLUSIONS
In the modern era of highly effective and specific therapies 
targeted to treat different disorders, efforts have to focus to 
identify the real composition of the used extracts of phyto-
cannabinoids. Concerning CBD, it is evident that it induces 
therapeutic effects that can be applied to control drug-resistant 
epilepsy. However, it is necessary to identify the types of epi-
lepsy responsive to the beneficial effects of CBD. In addition, 
it is essential to know its pharmacokinetic, side effects as well 
as the cellular and molecular effects induced by its repetitive 
and long-term administration, alone and associated with an-
tiseizure drugs.
Other important issue to consider is the evaluation of uncon-
ventional targets and mechanisms of action of CBD and other 
cannabinoids to control drug-resistant epilepsy and reduce fatal 
complications such as SUDEP. Several studies support that 
CBD decreases the expression and function of P-glycoprotein 
in different cell types. If CBD is able to diminish the overex-
pression of this transporter in the brain of patients with drug-re-
sistant epilepsy, it could be used as adjunctive therapy to better 
biodistribution and CNS access of antiseizure drugs.
Finally, a scientific validation of the antiepileptic prop-
erties of the different cannabinoids and their metabolites as 
well as terpenes (alone and in combination) would benefit 
in the control of different types of epilepsy. This validation 
should consider the genetic background to understand the pa-
tients’ response to cannabinoids.
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